替加环素作为多重耐药革兰氏阳性病原菌所致复杂植入物相关骨与关节感染患者抑制性抗菌治疗的安全性：TediSAT队列研究结果
Safety of Tedizolid as Suppressive Antimicrobial Therapy for Patients With Complex Implant-Associated Bone and Joint Infection due to Multidrug-Resistant Gram-Positive Pathogens: Results From the TediSAT Cohort Study.
作者信息
Ferry Tristan, Conrad Anne, Senneville Eric, Roux Sandrine, Dupieux-Chabert Céline, Dinh Aurélien, Lustig Sébastien, Goutelle Sylvain, Briot Thomas, Pham Truong-Thanh, Valour Florent
机构信息
Infectious Diseases Department, Croix-Rousse Hospital, Lyon, France.
French Referral Centre for Complex Bone and Joint Infections, Centre de Référence des Infections Ostéo-Articulaires complexes Lyon, Lyon, France.
出版信息
Open Forum Infect Dis. 2021 Jul 2;8(7):ofab351. doi: 10.1093/ofid/ofab351. eCollection 2021 Jul.
A prospective cohort study was conducted to evaluate long-term safety of tedizolid as suppressive antimicrobial treatment in patients with implant-associated bone and joint infection caused by multidrug-resistant gram-positive pathogens. Seventeen patients received tedizolid with a median duration of treatment of 6 months. No patients developed a serious adverse event.
进行了一项前瞻性队列研究，以评估替加环素作为抑制性抗菌治疗对由多重耐药革兰氏阳性病原体引起的植入物相关骨和关节感染患者的长期安全性。17名患者接受了替加环素治疗，中位治疗持续时间为6个月。没有患者发生严重不良事件。
Zotero 插件